Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransCode TherapeuticsRNAZ 34 EV-to-OCF is 0.08 as of Aug. 11, 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, TransCode Therapeutics ranks worse than 72.97% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, TransCode Therapeutics's Enterprise Value is $-1.67 Mil.
TransCode Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-21.40 Mil. Therefore, TransCode Therapeutics's EV-to-OCF for today is 0.08.
The historical rank and industry rank for TransCode Therapeutics's EV-to-OCF or its related term are showing as below:
RNAZ'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.08 Med: 0 Max: 0.08
Current: 0.08
During the past 7 years, the highest EV-to-OCF of TransCode Therapeutics was 0.08. The lowest was 0.08. And the median was .
RNAZ's EV-to-OCF is ranked worse than 72.97% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs RNAZ: 0.08
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TransCode Therapeutics's PE Ratio (TTM) for today is calculated as:
TransCode Therapeutics's share price for today is $3.88.
TransCode Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, TransCode Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransCode Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where TransCode Therapeutics's EV-to-OCF falls into.
TransCode Therapeutics's current Enterprise Value is $-1.67 Mil.
TransCode Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransCode Therapeutics (RNAZ) has a EV-to-OCF of 0.08 as of Aug. 11, 2026. Over the past decade, TransCode Therapeutics' EV-to-OCF has ranged from 0.08 to 0.08. According to the industry distribution chart, TransCode Therapeutics ranks #1026 out of 1406 companies in the Biotechnology industry, placing it in the top 73%.
Is TransCode Therapeutics' EV-to-OCF too high?
TransCode Therapeutics' current EV-to-OCF is 0.08. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.08. Based on the distribution chart, TransCode Therapeutics ranks #1026 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' EV-to-OCF compare to BCAB and APVO?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #1026 out of 1406 companies for EV-to-OCF. This places TransCode Therapeutics in the lower half of its industry. Historically, TransCode Therapeutics' own EV-to-OCF has ranged from 0.08 to 0.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. TransCode Therapeutics's current EV-to-OCF is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current EV-to-OCF of 0.08. The current EV-to-OCF is 0.08. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current EV-to-OCF is 0.08 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score
Get the complete analysis for RNAZ
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAZ has been successfully added to your 
